Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple …
WEB12 hours ago · More than half (55.5%) of patients treated with Sarclisa-VRd achieved MRD negative CR compared to 40.9% of patients taking VRd. Price Action: At last check on Monday, SNY stock was down 0.50% at ...
Isatuximab Plus VRd Approved by FDA for Newly Diagnosed, …
WEB1 day ago · An improvement in progression-free survival was reported with isatuximab plus VRd, with a 40% reduction in the risk of disease progression or death (hazard ratio = 0.60 [95% confidence interval (CI) = 0.44–0.81]; P = .0009); the median progression-free survival was not reached (NR; 95% CI = not reached to not reached) in the isatuximab-plus ...
Sarclisa Approved for Transplant-Ineligible Newly Diagnosed …
WEB10 hours ago · Results showed treatment with isatuximab plus VRd reduced the risk of disease progression or death by 40% compared with VRd alone (hazard ratio, 0.60 [95% CI, 0.44-0.81]; P =.0009). Median PFS was ...
FDA Approves Isatuximab With VRd as First-Line Option for …
WEB3 days ago · At 60 months, PFS rates were 83.2% in the isatuximab-VRd arm and 45.2% in the VRd arm. 2 The median PFS was not reached in the isatuximab-VRd arm vs 54.3 months (95% CI, 45.2–not reached) in the ...
FDA Approves Isatuximab Plus VRd in Transplant-Ineligible …
WEB3 days ago · Isatuximab plus VRd (isa-VRd) is now an FDA-approved combination for the treatment of patients with transplant-ineligible, newly diagnosed multiple myeloma, making it the first anti-CD38 therapy available in this patient population plus VRd. 1. In May 2024, the supplemental biologics license application of isatuximab for this indication was ...
FDA Approves Isatuximab/VRd in Newly Diagnosed Multiple …
WEB4 days ago · Transplant-ineligible patients 80 years or younger with NDMM in the prospective, open-label study across 102 sites and 21 countries were randomly assigned 3:2 to receive isa-VRd or VRd alone. Patients received 10 mg/kg of isatuximab intravenously once weekly for 5 weeks in the first 42-day cycle, followed by every other week up to cycle 4 ...
FDA Approves Isatuximab Plus VRd for Newly Diagnosed, …
WEB3 days ago · News. OncClub All Oncology News Pipeline Report. Media. ... VRd given as induction therapy in both arms consisted of 1.3 mg/m 2 of bortezomib on days 1, 4, 8, 11, 22, 25, ...
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone …
WEBDec 12, 2023 · An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple ...
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for …
WEBJun 3, 2024 · Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma.
Daratumumab Plus Standard Therapy for Multiple Myeloma
WEBJan 19, 2024 · Adding daratumumab (Darzalex) to standard VRD treatment helped people with newly diagnosed multiple myeloma live longer without their cancer getting worse or dying.